Clinical Trial Results:
A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in patients with essential hypertension
Summary
|
|
EudraCT number |
2004-002252-33 |
Trial protocol |
ES DE |
Global completion date |
17 Aug 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
12 Oct 2016
|
First version publication date |
12 Oct 2016
|
Other versions |
|
Summary report(s) |
CSPP100A2304_NovCTR |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.